Advertisement
UK markets close in 1 minute

  • FTSE 100

    7,897.98
    +20.93 (+0.27%)
     

  • FTSE 250

    19,393.35
    -57.32 (-0.29%)
     

  • AIM

    744.41
    -0.88 (-0.12%)
     

  • GBP/EUR

    1.1638
    -0.0045 (-0.39%)
     

  • GBP/USD

    1.2413
    -0.0025 (-0.20%)
     

  • Bitcoin GBP

    51,984.05
    +650.22 (+1.27%)
     

  • CMC Crypto 200

    1,375.46
    +62.83 (+5.03%)
     

  • S&P 500

    4,991.31
    -19.81 (-0.40%)
     

  • DOW

    37,929.89
    +154.51 (+0.41%)
     

  • CRUDE OIL

    83.17
    +0.44 (+0.53%)
     

  • GOLD FUTURES

    2,409.20
    +11.20 (+0.47%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,752.33
    -85.07 (-0.48%)
     

  • CAC 40

    8,027.02
    +3.76 (+0.05%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Teva to Present New Data for Fremanezumab

Sarah Collins
Updated
Teva to Present New Data for Fremanezumab

Today, Teva Pharmaceutical Industries (TEVA) announced that it will present new data for its migraine drug Fremanezumab, which is under review by the FDA for the preventive treatment as a monthly or quarterly injection, at the AHS’s (American Headache Society) 60th Annual Scientific Meeting in San Francisco. The event is being held from June 28 to July 1. Teva plans to present 23 abstracts, three oral presentations, and one late-breaking poster of Fremanezumab.

Continue reading